Newly-Developed Enzyme Could Treat Mysterious Multisystem Complications of COVID-19
|
By HospiMedica International staff writers Posted on 11 Aug 2020 |
|
Illustration
Scientists have developed a first-in-class DNASE1L3 enzyme analog, NTR-441, that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19.
The enzyme has been developed by Neutrolis (Cambridge, MA, USA), a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body. NTR-441, an engineered analog of the natural NET-destroying enzyme DNASE1L3, is the world's first investigational drug that can be systemically delivered to accurately target NETs.
NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. NETs are sticky, web-like structures made of chromatin—DNA studded with structural proteins—and expelled by suicidal neutrophils. NETs block air sacs and blood vessels in the lungs, trigger hyperinflammation and blood clotting (thrombosis), potentially causing irreversible end-organ damage and death.
Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19. In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs. NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.
"We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. "Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body. Thanks in part to competitive funding from the National Institutes of Health (R43HL150944), we will test whether NTR-441 is effective in ARDS, the most lethal manifestation of COVID-19."
Related Links:
Neutrolis
The enzyme has been developed by Neutrolis (Cambridge, MA, USA), a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body. NTR-441, an engineered analog of the natural NET-destroying enzyme DNASE1L3, is the world's first investigational drug that can be systemically delivered to accurately target NETs.
NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. NETs are sticky, web-like structures made of chromatin—DNA studded with structural proteins—and expelled by suicidal neutrophils. NETs block air sacs and blood vessels in the lungs, trigger hyperinflammation and blood clotting (thrombosis), potentially causing irreversible end-organ damage and death.
Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19. In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs. NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.
"We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. "Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body. Thanks in part to competitive funding from the National Institutes of Health (R43HL150944), we will test whether NTR-441 is effective in ARDS, the most lethal manifestation of COVID-19."
Related Links:
Neutrolis
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Rapid Sepsis Test
SeptiCyte RAPID
X-Ray Generator
Advantage Plus Generators
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Automated Phone Speech Test Identifies Alzheimer’s Pathology for Prescreening
Alzheimer’s disease assessment and trial recruitment often rely on costly, invasive biomarker testing and clinic-based cognitive evaluations, limiting scalability as populations age. Providers and trial... Read more
FDA-Cleared AI System Detects Sepsis Earlier and Reduces Mortality
Sepsis remains one of the deadliest complications for hospitalized patients, in part because its early signs overlap with other conditions. Each hour of delayed recognition measurably decreases survival,... Read more
Critical Care
view channel
Ring-Type Cuffless Monitor Becomes First Added to Official Hypertension Guidelines
Detecting nocturnal and morning hypertension often requires out-of-office assessment, but conventional cuff-type monitors can disrupt sleep. New national guidance in South Korea expands 24-hour monitoring... Read more
“Intelligent Tattoo” Method Detects Early Melanoma Signals
Melanoma is a lethal skin cancer in which earlier detection drives better outcomes. Current evaluation relies on visual inspection followed by biopsy, which can miss nascent lesions and lead to unnecessary... Read more
Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections
Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more
Surgical Techniques
view channel
Pink Noise Stimulation Approach Could Support Safer Anesthesia
Maintaining stable unconsciousness during general anesthesia while minimizing drug exposure remains a core perioperative challenge. Sudden nociceptive surges can disrupt anesthetic depth, increasing neurological... Read more
Surgical Robotic System Gains CE Mark for Minimally Invasive Procedures
Cornerstone Robotics’ (CSR; Hong Kong, China) Sentire Endoscopic Surgical System (Sentire Surgical System) has received European Union CE mark certification under the Medical Device Regulation (MDR) for... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
AI-Native EHR Achieves EU Medical Device Certification
InterSystems (Boston, MA, USA) announced that its IntelliCare electronic health record (EHR) solutions have been certified as Class IIa medical devices under the European Union Medical Device Regulation... Read more
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
Point of Care
view channel
Portable MRI System Accelerates Emergency Brain Imaging and Supports Triage
Emergency departments frequently face delays accessing conventional magnetic resonance imaging (MRI) for patients with suspected neurological emergencies. Such waits can slow triage, prolong boarding,... Read more
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read more
Business
view channel
Endologix Adds FDA-Cleared Peripheral Thrombectomy System
Endologix (Santa Rosa, CA, USA) has acquired the Pounce Thrombectomy System from Surmodics, with the transaction closing on May 18, 2026. The FDA-cleared system is indicated for the non-surgical removal... Read more
